louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00181129: Fatigue and Cancer Treatment(FACT)- an Exercise Intervention
Official title: Mitigating Cancer Treatment-Related Fatigue by Exercise
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Fatigue
Keywords: Fatigue
Cancer treatment
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 140
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this randomized controlled trial is to determine the effects of a nurse-directed, home-based walking exercise program to mitigate fatigue and maintain physical functioning during adjuvant therapy for cancer. The sample will be randomized into exercise (EX) or usual care (UC) groups. The independent study variable is participation in a walking exercise program. Outcomes include: fatigue, sleep disturbance, emotional distress, physical functioning and quality of life. The effects of the walking exercise program will be evaluated using self-report questionnaires administered pre- and post-treatment, patient diaries, and symptoms assessments at defined intervals during adjuvant therapy


Eligibility criteria: Inclusion Criteria:

Confirmed diagnosis of cancer (Stage 1,2,or 3),

21 years of age or older,

Free of cognitive or physical deficits that would preclude entry into study,

not currently exercising 120 min/wk or more

Exclusion Criteria:

Concurrent major health problems or disabilities that would limit participation in an exercise program.

Stage 4 cancer (metastisis)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University School of Nursing
state: Maryland
Study officials:
affiliation: Johns Hopkins University School of Nursing
name: Victoria L Mock, DNSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06946329: WATERinMOTION Aquatic Therapy in Obese Men With Knee Osteoarthritis
Official title: Mechanistic and Functional Outcomes of WATERinMOTION Aquatic Therapy in Obese Men With Knee Osteoarthritis: A Randomized Controlled Trial With 6-Month Follow-Up
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Osteoarthritis
Knee
Obesity
Keywords: Aquatic Therapy
Exercise Therapy
Quality of Life
Biomarkers
Wearable Electronic Devices
Lead sponsor: University of Sistan and Baluchestan
Sponsor class: OTHER
First posted: 2025-04-27
Enrollment: 100
Sex: MALE
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: TREATMENT

Brief summary: This RCT evaluates whether WATERinMOTION aquatic therapy improves pain, function, and quality of life more effectively than land-based exercise in obese men with knee osteoarthritis (OA). We will assess clinical outcomes (WOMAC), serum biomarkers (COMP, IL-6), and real-world activity (accelerometry) at baseline, 8 weeks, and 6 months.

Detailed description: 100 participants (BMI ≥30, age 45-65, radiographic knee OA) will be randomized to:

Aquatic group: 24 sessions over 8 weeks (3x/week) in 32°C water, progressing from buoyancy-assisted to resistance exercises.

Land group: Matched duration/intensity land-based rehabilitation. Primary outcomes: WOMAC pain/function. Secondary outcomes: SF-36 quality of life, serum COMP, 6-minute walk test, and accelerometer-measured step count.

Eligibility criteria: Inclusion Criteria:

* Males aged 45-65
* BMI ≥30 kg/m²
* Radiographic knee OA (Kellgren-Lawrence grade 2-3)
* WOMAC pain score ≥25/50

Exclusion Criteria:

* Inflammatory arthritis (e.g., rheumatoid)
* Intra-articular injections within 3 months
* Contraindications to aquatic exercise

Primary outcomes:
measure: WOMAC Pain Subscale
timeFrame: Baseline, 8 weeks, 6 months
measure: WOMAC Function Subscale
timeFrame: Baseline, 8 weeks, 6 months
Secondary outcomes:
measure: SF-36 Quality of Life
timeFrame: Baseline, 8 weeks, 6 months
measure: Serum COMP
timeFrame: Baseline, 8 weeks
measure: Daily Step Count
timeFrame: Continuous over 8 weeks
Other outcomes:
Locations:
city: Zahedan
country: Iran, Islamic Republic of
facility: Sport Sciences Department
state: Sistan And Baluchestan
Study officials:
affiliation: Assoc.Prof.Dr. of University of Sistan and Baluchestan, Zahedan, Iran
name: Mohammadreza Rezaeipour, MD,PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03019029: Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
Official title: Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Amyloidosis
Keywords: Peripheral Nerve Amyloidosis
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2017-01-12
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Participants with biopsy proven peripheral nerve amyloidosis will undergo an F-18 Florbetapir PET/MR scan
Primary purpose: DIAGNOSTIC

Brief summary: The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

Detailed description: Patients with pathologically proven amyloidosis involving the peripheral nervous system will undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A control arm comprised of patients with pathologically-confirmed non-amyloid causes of peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be reviewed for peripheral nerve uptake.

Eligibility criteria: Inclusion Criteria:

* Adults: 18-100
* Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed non-amyloid causes of peripheral neuropathy

Exclusion Criteria:

* Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)
* Claustrophobia
* BMI over 38

Primary outcomes:
measure: Locations of peripheral nerve 18-F Florbetapir uptake
timeFrame: 50-120 minutes post injection
measure: Pattern of F-18 Florbetapir uptake (Heterogeneous vs. Homogeneous, focal vs. diffuse)
timeFrame: 50-120 minutes post injection
Secondary outcomes:
measure: T1 and T2 characteristics (Hypointense, isointense or hyperintense relative to skeletal muscle)
timeFrame: 50-120 minutes post injection
measure: Morphologic changes
timeFrame: 50-120 minutes post injection
measure: Pattern of contrast enhancement (Solid, heterogeneous or peripheral enhancement)
timeFrame: 50-120 minutes post injection
measure: Additional sites of 18-F Florbetapir uptake
timeFrame: 50-120 minutes post injection
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Stephen M. Broski, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00305929: Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure
Official title: Phase II Study of Photodynamic Therapy With WST09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure - Repeat Procedure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostate Cancer
Keywords: Treatment of localized prostate cancer
Localized prostate cancer
Lead sponsor: STEBA France
Sponsor class: INDUSTRY
First posted: 2006-03-22
Enrollment: 8
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multi-centre, phase II, open-label, 12-month clinical trial for patients previously treated with WST09 (Tookad) who have positive prostate biopsies for cancer.

The study aims at delivering a second WST09 treatment for the purpose of eradicating the localized prostate cancer.

Detailed description: Multi-centre, phase II, open-label, 12-month clinical trial for patients that previously received a vascular-targeted photodynamic treatment (VTP) with WST09 (Tookad) and still have histological findings (prostate biopsies) indicating the presence of localized cancer.

The WST09-mediated VTP procedure consists of an I.V. infusion of WST09 (Tookad) at 2 mg/kg, in combination with the per-cutaneous interstitial delivery of monochromatic laser light (of a wavelength of 763nm) via the trans-perineal implantation of illumination fibres, positioned in the prostatic lobes.

In a previous Tookad trial, escalating doses of laser light were used with a fixed dose of WST09 (2 mg/kg) in patients with localized prostatic cancer. Patients who underwent the procedure but still have positive prostate biopsies (residual cancer) may benefit from an additional WTS09-mediated VTP procedure. Thus, the aim of this study is to treat patients still presenting with localized prostate cancer with a second WST09-mediated VTP procedure.

Eligibility criteria: Inclusion Criteria:

* Patients previously treated with WST09-mediated VTP, with a positive biopsy of the prostate 6 months following treatment
* Disease confined to the prostate
* Life expectancy greater than 5 years

Exclusion Criteria:

* Unwilling or unable to give informed consent
* Patients who have received another treatment for their prostate cancer since their previous WST09-mediated VTP

Primary outcomes:
measure: Prostate biopsy
timeFrame: 12 months
Secondary outcomes:
measure: MRI, PSA
timeFrame: 7 days, 6 months
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Prostate Centre Princess Margaret Hospital
state: Ontario
Study officials:
affiliation: University Health Network, Princess Margaret Hospital
name: John Trachtenberg, MD, FRCS(C)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02036229: Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis
Official title: a Randomised, Double Blind, Placebo Controlled, Half- Face Study to Evaluate the Effect of Topical Ivermectin Cream 0.5% on Demodicidosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Demodicidosis
Rosacea
Keywords: demodex
demodicidosis
rosacea
ivermectin
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2014-01-14
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether 0.5% ivermectin cream is effective in the treatment of demodicidosis (including papulopustular rosacea)


Eligibility criteria: Inclusion Criteria:

* subjects with clinical and laboratory diagnosis of demodicidosis with symmetrical facial eruption who are willing to comply with study requirements

Exclusion Criteria:

* known hypersensitivity to ivermectin.
* pregnancy
* immunodeficiency such as HIV or immunosuppressive therapy
* concomitant use of systemic antibiotics or steroids

Primary outcomes:
measure: A decrease in mite density in skin surface biopsy after treatment with topical ivermectin (≤5 mites/cm2 for skin lesions).
timeFrame: 5 months
Secondary outcomes:
measure: Clinical improvement
timeFrame: 5 months
measure: A comparable dermoscopic improvement in the demodicidosis features
timeFrame: 5 months
Other outcomes:
Locations:
city: Petah-Tiqva
country: Israel
facility: RabinMC, Dermatology dept.
Study officials:
affiliation: Rabin Medical Center
name: Rina Segal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04081129: Effect of Early Mobilization on Regional Lung Ventilation Assessed by EIT
Official title: Using EIT to Assess the Effect of Early Mobilization on Regional Lung Ventilation in ICU Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Critical Illness
Lung Function Decreased
ICU Acquired Weakness
Keywords: EIT
early mobilization
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2019-09-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adult patients was performed out-of-bed activity, who were sequentially admitted to the ICU

Brief summary: Changes in pulmonary ventilation and perfusion by EIT to out-of-bed activity in critically ill patients

Detailed description: 1. EIT measurements were performed in ICU patients who under out-of-bed activity
2. Measurement of EIT was taken place at 4 time points: supine position before early mobilization, 30min, 60min during early mobilization, supine positon after early mobilization. All of them were without invasive ventilation. Measurements were made in triplicate at all time points.

Eligibility criteria: Inclusion Criteria:

* adult patients was performed out-of-bed activity in the ICU department based on doctor order
* Age (\> 18 years old) and (\< 90 years old)

Exclusion Criteria:

* Chest skin is injury and cannot be monitored by EIT
* The patients or their families refused to participate in the study

Primary outcomes:
measure: lung regional ventilation distribution
timeFrame: Hour 1
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
References:
citation: Yuan S, Chi Y, Long Y, He H, Zhao Z. Effect of Position Change From the Bed to a Wheelchair on the Regional Ventilation Distribution Assessed by Electrical Impedance Tomography in Patients With Respiratory Failure. Front Med (Lausanne). 2021 Nov 4;8:744958. doi: 10.3389/fmed.2021.744958. eCollection 2021.
Clinical trial NCT06129929: Effectiveness of Using Jiu-Jitsu for Coping With Medical Violence in Healthcare Workers
Official title: Using Kolb's Experiential Learning Program to Promote Nurse Effectiveness for Coping With Workplace Violence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Educational Problems
Workplace Violence
Nursing
Keywords: education
Lead sponsor: National Defense Medical Center, Taiwan
Sponsor class: OTHER
First posted: 2023-11-13
Enrollment: 396
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Workplace violence in hospitals and other health care settings is a troublesome issue and has severe consequences for the entire health care system. In recent years, workplace violence has made a great threat to nurse assistants. Therefore, violence prevention education is a part of medical personnel's job responsibility. However, a theory-based violence prevention education program for healthcare settings was limited. The aim of the study is to investigate the effects of experiential learning theory-based medical jujitsu training on perception on violence, attitude on violence, self-efficacy, and turnover intention among nurse assistants


Eligibility criteria: Inclusion Criteria:

* Licensed healthcare professionals

Exclusion Criteria:

* Non-licensed healthcare professionals

Primary outcomes:
measure: Self efficacy
timeFrame: pre and post intervention
Secondary outcomes:
measure: Perception of Aggression
timeFrame: pre and post intervention
measure: Aggression and violence attitude
timeFrame: pre and post intervention
measure: Turnover Intentions
timeFrame: pre and post intervention
Other outcomes:
Locations:
city: Taipei city
country: Taiwan
facility: TSGH
Study officials:
References:
Clinical trial NCT05908929: PRF Therapy for Pocket Reduction
Official title: Comparative Evaluation of Clinical Parameters in Early-Stage III Grade A Periodontitis Patients After Insertion of Platelet Rich Fibrin as Step 2 Phase I Therapy in Periodontal Pockets: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periodontal Pocket
Periodontitis
Lead sponsor: Federico II University
Sponsor class: OTHER
First posted: 2023-06-18
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Periodontal regenerative therapy has focused on various non-surgical and surgical treatment methods. Platelet-rich fibrin (PRF) has shown to possess multiple uses, including properties that promote healing of both soft and hard tissues. In the present study, we hypothesized that the addition of PRF into periodontal pockets, as an adjunct to conventional scaling and root planing (SRP), would enhance the outcomes of non-surgical periodontal therapy. This split-mouth randomized controlled clinical trial included 26 periodontal pocket sites in 13 patients with periodontitis. The pockets were randomly assigned as either test or control sites. In the test group, PRF was placed as an adjunct to SRP, while the control group received SRP alone. Probing pocket depths (PPD), clinical attachment levels (CAL), gingival recession (GR), plaque index (PI), and gingivitis index (GI) were measured at baseline and at six weeks. The wound healing index was measured during the six-week follow-up period.


Eligibility criteria: Inclusion Criteria:

* either gender,
* aged 18 years or older,
* patients without a medical history of systemic diseases,
* patient with chronic periodontitis
* patient with 5 or 6 mm of probing depth

Exclusion Criteria:

* patients with medical history of systemic disease or bleeding disorders
* presence of other gingival diseases (such as leukoplakia, lichen planus, pemphigoid disorders, pemphigus vulgaris, herpetic lesions, Necrotizing Ulcerative Periodontitis (NUP)
* pregnancy
* history of any drug usage affecting the periodontium for the past six months (such as systemic antibiotic therapy)
* previous periodontal treatment in the last six months
* smoking
* teeth with untreated caries
* endodontic lesions and grade II or more mobility
* subjects with acute exacerbation of periodontitis
* patients with systemic
* disease or condition that could affect tissue healing (e.g., autoimmune disease)
* severe furcation involvement (grade II and III)
* abutment for prosthetic rehabilitation
* active orthodontic therapy

Primary outcomes:
measure: pocket depth
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Naples
country: Italy
facility: University of Naples Federico II
city: Napoli
country: Italy
facility: Università degli Studi di Napoli Federico II
Study officials:
References:
Clinical trial NCT04664829: The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Official title: Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Metastatic Triple-Negative Breast Carcinoma
Keywords: Bexarotene
Lead sponsor: National Cancer Centre, Singapore
Sponsor class: OTHER
Collaborators: name: National Medical Research Council (NMRC), Singapore
First posted: 2020-12-11
Enrollment: 12
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance.

Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour.

The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.


Eligibility criteria: Inclusion Criteria:

* Patients with histologically or cytologically proven metastatic TNBC
* Patients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil
* Females aged 21 years and older
* ECOG performance status 0 or 1
* Life expectancy greater than three months
* Patients have normal organ and marrow function
* Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment

Exclusion Criteria:

* Previous palliative radiotherapy to potentially biopsy-able lesion
* Active symptomatic central nervous system (CNS) metastases
* Spinal cord compression not definitively treated with surgery and/or radiation
* Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures

Primary outcomes:
measure: Tumour transcriptome by RNA sequencing
timeFrame: From time of first biopsy before the start of treatment, to disease progression, up to 2 years
measure: Tumour protein profile by multiplex immunohistochemistry
timeFrame: From time of first biopsy before the start of study treatment, to disease progression, up to 2 years
Secondary outcomes:
measure: Incidences of treatment related adverse events
timeFrame: From time of start of study treatment, to 28 days after last dose of study treatment, up to 2 years
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National Cancer Center Singapore
Study officials:
affiliation: National Cancer Centre, Singapore
name: Elaine Lim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00937729: Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules
Official title: Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment Containing Enfuvirtide (Fuzeon) Associated With Two Active Molecules
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: HIV1 Infection
HIV Infections
Keywords: uncompliant patients with virological failure
Treatment experienced
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
First posted: 2009-07-13
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients HIV1 infected in virological failure (viral load \> 50 copies/ml) by lack of compliance,old of more than 18 years, who never received enfuvirted and without opportunistic infection, yet treated by almost one molecule of each group.

Brief summary: In case of lack of compliance in HIV1 patients, the investigators hope to prove that enfuvirtide injection during almost 3 months, with nurse help at home and therapeutic education may contribute to obtain a good compliance more than 95% in these patients.


Eligibility criteria: Inclusion Criteria:

* virological failure, more than 18 years, prouved lack of compliance, with no sub-optimal treatment, in ambulatory status.

Exclusion Criteria:

* hospitalization,HIV2 infection,pregnancy,preliminary treatment with enfuvirtide,chimiotherapy , opportunistic infection in progress

Primary outcomes:
measure: viral load compliance
timeFrame: one year
Secondary outcomes:
measure: statistical analysis of MOS HIV
timeFrame: one year
Other outcomes:
Locations:
city: Rouen
country: France
facility: Borsa-Lebas
Study officials:
affiliation: CHU Hôpitaux de Rouen
name: BORSA-LEBAS Françoise
role: PRINCIPAL_INVESTIGATOR
References: